EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 23 / No 2 (Février 2007) Med Sci (Paris), 23 2 (2007) 167-172 References
Free Access
Issue
Med Sci (Paris)
Volume 23, Number 2, Février 2007
Page(s) 167 - 172
Section M/S revues
DOI https://doi.org/10.1051/medsci/2007232167
Published online 15 February 2007
  1. Billingham RE, Brent L, Medawar PB. Actively acquired tolerance to foreign cells. Nature 1953; 172 : 603–6. [Google Scholar]
  2. Brent L, Courtenay T, Gowland G. Immunological reactivity of lymphoid cells after treatment with anti-lymphocytic serum. Nature 1967; 215 : 1461–4. [Google Scholar]
  3. Dresser DW. Specific inhibition of antibody production. II. Paralysis induced in adult mice by small quantities of protein antigen. Immunology 1962; 5 : 378–88. [Google Scholar]
  4. Sakaguchi S. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004; 22 : 531–62. [Google Scholar]
  5. Bach JF. Regulatory T cells under scrutiny. Nat Rev Immunol 2003; 3 : 189–98. [Google Scholar]
  6. Chatenoud L, Salomon B, Bluestone JA. Suppressor T cells. They’re back and critical for regulation of autoimmunity! Immunol Rev 2001; 182 : 149–63. [Google Scholar]
  7. Bach JF. Insulin-dependent diabetes mellitus as an autoimmune disease. Endocrine Rev 1994; 15 : 516–42. [Google Scholar]
  8. Kaufman DL, Clare-Salzler M, Tian J, et al. Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes. Nature 1993; 366 : 69–72. [Google Scholar]
  9. Tisch R, Yang X D, Singer SM, et al. Immune response to glutamic acid decarboxylase correlates with insulitis in non-obese diabetic mice. Nature 1993; 366 : 72–5. [Google Scholar]
  10. Elias D, Meilin A, Ablamunits V, et al. Hsp60 peptide therapy of NOD mouse diabetes induces a Th2 cytokine burst and downregulates autoimmunity to various beta-cell antigens. Diabetes 1997; 46 : 758–64. [Google Scholar]
  11. Tian J D, Claresalzler M, Herschenfeld A, et al. Modulating autoimmune responses to GAD inhibits disease progression and prolongs islet graft survival in diabetes-prone mice. Nat Med 1996; 2 : 1348–53. [Google Scholar]
  12. Tian J, Lehmann PV, Kaufman DL. Determinant spreading of T helper cell 2 (Th2) responses to pancreatic islet autoantigens. J Exp Med 1997; 186 : 2039–43. [Google Scholar]
  13. Sospedra M, Martin R. Antigen-specific therapies in multiple sclerosis. Int Rev Immunol 2005; 24 : 393–413. [Google Scholar]
  14. Weiner HL, Mackin GA, Matsui M, et al. Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science 1993; 259 : 1321–4. [Google Scholar]
  15. Barnett ML, Kremer JM, St Clair EW, et al. Treatment of rheumatoid arthritis with oral type II collagen. Results of a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 1998; 41 : 290–7. [Google Scholar]
  16. Barnett ML, Combitchi D, Trentham DE. A pilot trial of oral type II collagen in the treatment of juvenile rheumatoid arthritis. Arthritis Rheum 1996; 39 : 623–8. [Google Scholar]
  17. Nussenblatt RB, Gery I, Weiner HL, et al. Treatment of uveitis by oral administration of retinal antigens : Results of a phase I/II randomized masked trial. Am J Ophthalmol 1997; 123 : 583–92. [Google Scholar]
  18. Chaillous L, Lefevre H, Thivolet C, et al. Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial. Diabete insuline orale group. Lancet 2000; 356 : 545–9. [Google Scholar]
  19. Ergun-Longmire B, Marker J, Zeidler A, et al. Oral insulin therapy to prevent progression of immune-mediated (type 1) diabetes. Ann NY Acad Sci 2004; 1029 : 260–77. [Google Scholar]
  20. Skyler J. Effects of insulin in relatives of patients with type 1 diabetes mellitus. Diabetes prevention trial-type 1 diabetes study group. N Engl J Med 2002; 346 : 1685–91. [Google Scholar]
  21. Raz I, Elias D, Avron A, et al. Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial. Lancet 2001; 358 : 1749–53. [Google Scholar]
  22. Brocke S, Gijbels K, Allegretta M, et al. Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein. Nature 1996; 379 : 343–6. [Google Scholar]
  23. Clevers H, Alarcon B, Wileman T, et al. The T cell receptor/CD3 complex: a dynamic protein ensemble. Annu Rev Immunol 1988; 6 : 629–62. [Google Scholar]
  24. Chatenoud L, Primo J, Bach J F. CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. J Immunol 1997; 158 : 2947–54. [Google Scholar]
  25. Chatenoud L, Thervet E, Primo J, et al. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci USA 1994; 91 : 123–7. [Google Scholar]
  26. Chatenoud L. CD3-specific antibody-induced active tolerance: from bench to bedside. Nat Rev Immunol 2003; 3 : 123–32. [Google Scholar]
  27. Belghith M, Bluestone JA, Barriot S, et al. TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat Med 2003; 9 : 1202–8. [Google Scholar]
  28. Yasunami R, Bach JF. Anti-suppressor effect of cyclophosphamide on the development of spontaneous diabetes in NOD mice. Eur J Immunol 1988; 18 : 481–4. [Google Scholar]
  29. Mahiou J, Walter U, Lepault F, et al. In vivo blockade of the Fas-Fas ligand pathway inhibits cyclophosphamide-induced diabetes in NOD mice. J Autoimmun 2001; 16 : 431–40. [Google Scholar]
  30. Cosimi AB, Colvin RB, Burton RC, et al. Use of monoclonal antibodies to T-cell subsets for immunologic monitoring and treatment in recipients of renal allografts. N Engl J Med 1981; 305 : 308–14. [Google Scholar]
  31. Ortho multicenter transplant study group. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med 1985; 313 : 337–42. [Google Scholar]
  32. Chatenoud L, Ferran C, Legendre C, et al. In vivo cell activation following OKT3 administration. Systemic cytokine release and modulation by corticosteroids. Transplantation 1990; 49 : 697–702. [Google Scholar]
  33. Abramowicz D, Schandene L, Goldman M, et al. Release of tumor necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients. Transplantation 1989; 47 : 606–8. [Google Scholar]
  34. Kohm AP, Williams JS, Bickford AL, et al. Treatment with nonmitogenic anti-CD3 monoclonal antibody induces CD4+ T cell unresponsiveness and functional reversal of established experimental autoimmune encephalomyelitis. J Immunol 2005; 174 : 4525–34. [Google Scholar]
  35. Ludviksson BR, Ehrhardt RO, Strober W. TGF-beta production regulates the development of the 2,4,6-trinitrophenol-conjugated keyhole limpet hemocyanin-induced colonic inflammation in IL-2-deficient mice. J Immunol 1997; 159 : 3622–8. [Google Scholar]
  36. Alegre ML, Peterson LJ, Xu D, et al. A non-activating « humanized » anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo. Transplantation 1994; 57 : 1537–43. [Google Scholar]
  37. Bolt S, Routledge E, Lloyd I, et al. The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties. Eur J Immunol 1993; 23 : 403–11. [Google Scholar]
  38. Woodle ES, Xu D, Zivin RA, et al. Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gamma1(Ala-Ala) in the treatment of acute renal allograft rejection. Transplantation 1999; 68 : 608–16. [Google Scholar]
  39. Friend PJ, Hale G, Chatenoud L, et al. Phase I study of an engineered aglycosylated humanized CD3 antibody in renal transplant rejection. Transplantation 1999; 68 : 1632–7. [Google Scholar]
  40. Herold KC, Hagopian W, Auger JA, et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002; 346 : 1692–8. [Google Scholar]
  41. Herold KC, Gitelman SE, Masharani U, et al. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 2005; 54 : 1763–9. [Google Scholar]
  42. Keymeulen B, Vandemeulebroucke E, Ziegler A G, et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005; 352 : 2598–608. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.